Blog
RSS Feed- All categories
- England (NICE)
-
All tags
- Academia
- Accelerated review
- Affordability
- Application
- Arthritis
- Artificial intelligence
- Asthma
- Australia
- Bias
- Biosimilar
- Blood product
- Breakthrough therapy designation
- Brexit
- Budget
- Budget impact analysis
- Canada
- Cancer
- Cancer Drugs Fund
- Cardiovascular disease
- Cellular therapy
- Children
- Clinical trial
- Collaboration
- Columbia
- Combination product
- Comparison
- Compassionate use
- Conference
- Conflict of interest
- Consultation
- Cost analysis
- Cost effectiveness
- Costs
- COVID-19
- Data
- Database
- Decision making
- Delisting
- Denmark
- Development
- Device
- Diagnostic agent
- Digital health
- Dossier
- Drug development
- Drug utilisation
- Economic evaluation
- Engagement
- England
- Equity
- Europe
- Expenditure
- Fast track
- Fees and charges
- Formulary
- Framework
- France
- Free trade agreement
- Funding
- Future
- Gene therapy
- Generic medicine
- Germany
- Global
- Guidelines
- Health care system
- Health plans
- Health policy
- Health related quality of life
- Health technology assessment
- Hepatitis C
- HIV infection
- Hypercholesterolaemia
- Innovation
- Intellectual property
- Investment
- Ireland
- Listing
- MAESTrO
- Managed entry scheme
- Management
- Market access
- Medicare
- Medicine
- Merger & acquisition
- Meta-analysis
- Modelling & simulation
- Multiple sclerosis
- New Zealand
- NHS
- NICE
- Northern Ireland
- Orphan drug
- Outcome
- Paediatrics
- Patent protection
- Patient
- Patient registry
- Perspective
- Pharmaceutical industry
- Pharmacy
- Pilot
- Pricing
- Procedure
- Process
- Productivity
- Project
- Proposal
- Public health
- Publication
- Real world evidence
- Regenerative medicine
- Regulation
- Reimbursement
- Report
- Request for proposals (RFP)
- Review
- Risk sharing agreement
- Safety
- Scientific advice
- Scotland
- Software
- Standards
- Submission
- Supply
- Surrogate outcome
- Survey
- Sweden
- Systematic review
- Targeted therapy
- Taxation
- Timelines
- Transparency
- Treatment algorithm
- Type 2 diabetes mellitus
- UK
- US
- Vaccine
- Validation
- Value
- Wales
- Wastage
- Wonder Drug Consulting
- Workshop
Posted by Michael Wonder on 16 Oct 2023
UK faces £50 billion economic hit due to spiralling medicines levy
12 October 2023 - A year on from the publication of analysis, which found that excessive double digit UK rebates ...